Citizens JMP Raises PT on ABIVAX Société Anonyme (ABVX) Stock

ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 25, Citizens JMP lifted the price target on the company’s stock to $114 from $95, while keeping an “Outperform” rating, as reported by The Fly. This announcement follows ABIVAX Société Anonyme (NASDAQ:ABVX) stating that results from the Obefazimod Phase 3 induction trials would be presented next month. As per the firm, the Phase 3 results can reinforce the strength of Obefazimod’s efficacy and increase conviction in the multi-billion-dollar sales potential.

Citizens JMP Raises PT on ABIVAX Société Anonyme (ABVX) Stock

ABIVAX Société Anonyme (NASDAQ:ABVX)’s operating loss rose by EUR 13.7 million to EUR -93.7 million for the 6 months to June 30, 2025, compared to EUR -80.0 million for the same period of the previous year. Operating income, consisting mainly of Research Tax Credit and Subsidies, fell by EUR 4.7 million to EUR 2.1 million for 6 months to June 30, 2025, as compared to EUR 6.8 million for 6 months ending June 30, 2024. The rise in operating loss was due to the operating expenses.

While we acknowledge the potential of ABVX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABVX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.